A clinical trial combining an IDO1 inhibitor with a therapeutic melanoma vaccine did not boost tumor-fighting T cells as intended, according to the disclosed trial results led by Craig L. Slingluff of the University of Virginia. Investigators tested whether blocking IDO1, an immunosuppressive enzyme in tumors, would amplify vaccine-driven immune responses. The outcome, described as scientifically valuable despite lack of the anticipated immunologic effect, points to limits in translating IDO1 blockade into measurable gains for the selected endpoints. The work underscores the importance of identifying which tumor immune contexts actually respond to IDO1 targeting. For drug developers, the negative immunology signal may inform biomarker selection and combination strategy refinement in future melanoma vaccine programs and broader checkpoint-adjacent vaccine efforts.